Clinical-imaging-pathological correlation in pulmonary hypertension associated with left heart disease.

Authors:
van de Veerdonk MC; Roosma L; Trip P; Gopalan D; Vonk Noordegraaf A and 2 more

Journal:
Eur Respir Rev

Publication Year: 2024

DOI:
10.1183/16000617.0144-2023

PMCID:
PMC10900069

PMID:
38417969

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur Respir Rev

Abbreviation: Eur Respir Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
An update on diagnosis and management of obstructive sleep apnoea in the first 2 years of life.
Polytarchou A; Moudaki A; Van de Perck E and 4 more (2024) - Transparency Score: 2/6
Eradication treatment for <i>Pseudomonas aeruginosa</i> infection in adults with bronchiectasis: a …
Conceição M; Shteinberg M; Goeminne P and 2 more (2024) - Transparency Score: 3/6
From treatable traits to GETomics in airway disease: moving towards clinical practice.
Papi A; Faner R; Pavord I and 6 more (2024) - Transparency Score: 3/6
Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis.
Krabbe J; Steffens KM; Drießen S and 1 more (2024) - Transparency Score: 4/6
Pulmonary veno-occlusive disease: illustrative cases and literature review.
Lechartier B; Boucly A; Solinas S and 5 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: E.J. Nossent and A. Vonk Noordegraaf have received speaker fees for lectures and educational events from Janssen, MSD and United Therapeutics/Ferrer. E.J. Nossent has received consulting fees from Janssen, MSD and United Therapeutics/Ferrer and A. Vonk Noordegraaf from Janssen, MSD and United Therapeutics/Ferrer. The other authors did not report any conflict of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025